C₁₆H₁₅N₂O₆P (P274)
Quantities
| P4250 | defined daily dose | 0.45 |
| P2067 | mass | 362.067 |
| P3780 | active ingredient in | ... | Q47521338 (Cerebyx) | Cerebyx |
| P233 | canonical SMILES | String | C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3 | ??? |
| P373 | Commons category | String | Fosphenytoin | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P8224 | image of molecular model or crystal lattice model | CommonsMedia | http://commons.wikimedia.org/wiki/Special:FilePath/Fosphenytoin%203D%20ball.png | ??? |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P3493 | legal status (medicine) | ... | Q879952 (boxed warning) | boxed warning |
| P2175 | medical condition treated | ... | Q41571 (epilepsy) | epilepsy |
| P2175 | medical condition treated | ... | Q980709 (status epilepticus) | status epilepticus |
| P2175 | medical condition treated | ... | Q18554191 (visual epilepsy) | visual epilepsy |
| P3489 | pregnancy category | ... | Q28123618 (US pregnancy category D) | US pregnancy category D |
| P769 | significant drug interaction | ... | Q169569 (metronidazole) | metronidazole |
| P769 | significant drug interaction | ... | Q282629 (vinblastine) | vinblastine |
| P769 | significant drug interaction | ... | Q407617 (sertraline) | sertraline |
| P769 | significant drug interaction | ... | Q408535 (quetiapine) | quetiapine |
| P769 | significant drug interaction | ... | Q408637 (dronedarone) | dronedarone |
| P769 | significant drug interaction | ... | Q408977 (vincristine) | vincristine |
| P769 | significant drug interaction | ... | Q409236 (fluvoxamine) | fluvoxamine |
| P769 | significant drug interaction | ... | Q409492 (cimetidine) | cimetidine |
| P769 | significant drug interaction | ... | Q422229 (diltiazem) | diltiazem |
| P769 | significant drug interaction | ... | Q422244 (fluoxetine) | fluoxetine |
| P769 | significant drug interaction | ... | Q409665 (disulfiram) | disulfiram |
| P769 | significant drug interaction | ... | Q410061 (amiodarone) | amiodarone |
| P769 | significant drug interaction | ... | Q411648 (tacrolimus) | tacrolimus |
| P769 | significant drug interaction | ... | Q412415 (cisplatin) | cisplatin |
| P769 | significant drug interaction | ... | Q419319 (bortezomib) | bortezomib |
| P769 | significant drug interaction | ... | Q411188 (aripiprazole) | aripiprazole |
| P769 | significant drug interaction | ... | Q411478 (fluconazole) | fluconazole |
| P769 | significant drug interaction | ... | Q422654 (saquinavir) | saquinavir |
| P769 | significant drug interaction | ... | Q423111 (vemurafenib) | vemurafenib |
| P769 | significant drug interaction | ... | Q423169 (isoniazid) | isoniazid |
| P769 | significant drug interaction | ... | Q423762 (paclitaxel) | paclitaxel |
| P769 | significant drug interaction | ... | Q425729 (ivabradine) | ivabradine |
| P769 | significant drug interaction | ... | Q3011604 (dabrafenib) | dabrafenib |
| P769 | significant drug interaction | ... | Q5186964 (crizotinib) | crizotinib |
| P769 | significant drug interaction | ... | Q7157043 (pazopanib) | pazopanib |
| P769 | significant drug interaction | ... | Q773449 (L-thyroxine) | L-thyroxine |
| P769 | significant drug interaction | ... | Q7914515 (vandetanib) | vandetanib |
| P769 | significant drug interaction | ... | Q27139135 (dasatinib monohydrate) | dasatinib monohydrate |
| P769 | significant drug interaction | ... | Q75163056 (rac-miconazole) | rac-miconazole |
| P279 | subclass of | ... | Q11173 (chemical compound) | chemical compound |
| P2868 | subject has role | ... | Q576618 (anticonvulsant agent) | anticonvulsant agent |
| P267 | ATC code | N03AB05 |
| P231 | CAS Registry Number | 93390-81-9 |
| P683 | ChEBI ID | 5165 |
| P592 | ChEMBL ID | CHEMBL1201336 |
| P661 | ChemSpider ID | 50839 |
| P715 | DrugBank ID | DB01320 |
| P11198 | DrugCentral ID | 1247 |
| P8494 | DSSTOX compound identifier | DTXCID7024299 |
| P3117 | DSSTox substance ID | DTXSID9044299 |
| P646 | Freebase ID | /m/073l73 |
| P595 | Guide to Pharmacology Ligand ID | 7190 |
| P2062 | HSDB ID | 7523 |
| P2057 | Human Metabolome Database ID | HMDB0015417 |
| P234 | InChI | InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23) |
| P235 | InChIKey | XWLUWCNOOVRFPX-UHFFFAOYSA-N |
| P665 | KEGG ID | C07840 |
| P665 | KEGG ID | D07993 |
| P10245 | MedlinePlus drug identifier | a619063 |
| P486 | MeSH descriptor ID | C043114 |
| P6366 | Microsoft Academic ID (discontinued) | 2776430242 |
| P2115 | NDF-RT ID | N0000022035 |
| P4235 | PatientsLikeMe treatment ID | fosphenytoin |
| P11199 | Probes And Drugs ID | PD009565 |
| P662 | PubChem CID | 56339 |
| P3345 | RxNorm CUI | 72236 |
| P2877 | SureChEMBL ID | 94254 |
| P2892 | UMLS CUI | C0244656 |
| P11089 | UniChem compound ID | 265581 |
| P652 | UNII | B4SF212641 |
| P11143 | WikiProjectMed ID | Fosphenytoin |
Why not click here or view trends?
log id: 4040127